Prospects for improving neovascularization of the ischemic heart: Lessons from development

Microcirculation

Volumn 24, Issue 1, 2017, Pages

  Smart, Nicola ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

coronary vasculature; endocardium; epicardium; neovascularization; sinus venosus

Indexed keywords

ANGIOGENESIS; BLOOD VESSEL WALL; CAPILLARY DENSITY; CAUSAL ATTRIBUTION; CELL EXPANSION; CELL MATURATION; CELL POPULATION; CORONARY SMOOTH MUSCLE CELL; EMBRYO DEVELOPMENT; ENDOCARDIUM; EPICARDIUM; FIBROBLAST; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MACROPHAGE; MOLECULAR DYNAMICS; NONHUMAN; PERICYTE; REVIEW; STEM CELL; TREATMENT PLANNING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CORONARY BLOOD VESSEL; EMBRYOLOGY; GROWTH, DEVELOPMENT AND AGING; HEART MUSCLE ISCHEMIA; REGENERATION;

ANIMALS; CORONARY VESSELS; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION;

EID: 85010908786     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12335     Document Type: Review

References (174)

1. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101:359–372.
2. Fishbein MC, Y-Rit J, Lando U, Kanmatsuse K, Mercier JC, Ganz W. The relationship of vascular injury and myocardial hemorrhage to necrosis after reperfusion. Circulation. 1980;62:1274–1279.
3. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496–1508.
4. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359–1365.
5. Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105:788–793.
6. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol. 2007;49:1015–1026.
7. Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674–2682.
8. Norman S, Riley PR. Anatomy and development of the cardiac lymphatic vasculature: its role in injury and disease. Clin Anat. 2016;29:305–315.
9. Ratajska A, Gula G, Flaht-Zabost A et al. Comparative and developmental anatomy of cardiac lymphatics. ScientificWorldJournal. 2014;2014:183170.
10. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–395.
11. Saraf R, Mahmood F, Amir R, Matyal R. Neuropeptide Y is an angiogenic factor in cardiovascular regeneration. Eur J Pharmacol. 2016;776:64–70.
12. Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci. 2015;129:1173–1193.
13. Yu AY, Shimoda LA, Iyer NV et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest. 1999;103:691–696.
14. Siu CW, Liao SY, Liu Y, Lian Q, Tse HF. Stem cells for myocardial repair. Thromb Haemost. 2010;104:6–12.
15. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 1996;270:H1803–H1811.
16. Levy AP. Hypoxic regulation of VEGF mRNA stability by RNA-binding proteins. Trends Cardiovasc Med. 1998;8:246–250.
17. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease—part I. Cardiol Rev. 2008;16:163–171.
18. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease—Part II. Cardiol Rev. 2008;16:219–229.
19. Rivard A, Fabre JE, Silver M et al. Age-dependent impairment of angiogenesis. Circulation. 1999;99:111–120.
20. Emanueli C, Caporali A, Krankel N, Cristofaro B, Van LS, Madeddu P. Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci. 2007;12:2003–2012.
21. Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol. 1999;154:355–363.
22. Yoon YS, Uchida S, Masuo O et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation. 2005;111:2073–2085.
23. −/− mice. Circulation. 1999;99:3188–3198.
24. Ren G, Michael LH, Entman ML, Frangogiannis NG. Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem. 2002;50:71–79.
25. Paku S, Paweletz N. First steps of tumor-related angiogenesis. Lab Invest. 1991;65:334–346.
26. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA. 1995;92:7657–7661.
27. Pettersson A, Nagy JA, Brown LF et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000;80:99–115.
28. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591–1598.
29. Virag JI, Murry CE. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol. 2003;163:2433–2440.
30. Khand A, Fisher M, Jones J, Patel B, Perry R, Mitsudo K. The collateral circulation of the heart in coronary total arterial occlusions in man: systematic review of assessment and pathophysiology. Am Heart J. 2013;166:941–952.
31. Seiler C, Meier P. Historical aspects and relevance of the human coronary collateral circulation. Curr Cardiol Rev. 2014;10:2–16.
32. He L, Liu Q, Hu T et al. Genetic lineage tracing discloses arteriogenesis as the main mechanism for collateral growth in the mouse heart. Cardiovasc Res. 2016;109:419–430.
33. Nolan DJ, Ciarrocchi A, Mellick AS et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007;21:1546–1558.
34. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221–228.
35. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430–436.
36. Gulati R, Jevremovic D, Witt TA et al. Modulation of the vascular response to injury by autologous blood-derived outgrowth endothelial cells. Am J Physiol Heart Circ Physiol. 2004;287:H512–H517.
37. Richardson MR, Yoder MC. Endothelial progenitor cells: quo vadis? J Mol Cell Cardiol. 2011;50:266–272.
38. Smart N, Riley PR. The stem cell movement. Circ Res. 2008;102:1155–1168.
39. Psaltis PJ, Simari RD. Vascular wall progenitor cells in health and disease. Circ Res. 2015;116:1392–1412.
40. Klein D, Weisshardt P, Kleff V, Jastrow H, Jakob HG, Ergun S. Vascular wall-resident CD44 + multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation. PLoS One. 2011;6:e20540.
41. Pasquinelli G, Tazzari PL, Vaselli C et al. Thoracic aortas from multiorgan donors are suitable for obtaining resident angiogenic mesenchymal stromal cells. Stem Cells. 2007;25:1627–1634.
42. Tang Z, Wang A, Yuan F et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun. 2012;3:875.
43. Psaltis PJ, Puranik AS, Spoon DB et al. Characterization of a resident population of adventitial macrophage progenitor cells in postnatal vasculature. Circ Res. 2014;115:364–375.
44. Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood. 2005;105:2783–2786.
45. Stapor PC, Sweat RS, Dashti DC, Betancourt AM, Murfee WL. Pericyte dynamics during angiogenesis: new insights from new identities. J Vasc Res. 2014;51:163–174.
46. Hu Y, Zhang Z, Torsney E et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004;113:1258–1265.
47. Majesky MW, Dong XR, Hoglund V, Mahoney WM Jr, Daum G. The adventitia: a dynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol. 2011;31:1530–1539.
48. Majesky MW, Dong XR, Regan JN, Hoglund VJ. Vascular smooth muscle progenitor cells: building and repairing blood vessels. Circ Res. 2011;108:365–377.
49. Psaltis PJ, Harbuzariu A, Delacroix S, Holroyd EW, Simari RD. Resident vascular progenitor cells–diverse origins, phenotype, and function. J Cardiovasc Transl Res. 2011;4:161–176.
50. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21:193–215.
51. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003;314:15–23.
52. Kelly-Goss MR, Sweat RS, Stapor PC, Peirce SM, Murfee WL. Targeting pericytes for angiogenic therapies. Microcirculation. 2014;21:345–357.
53. Katare R, Riu F, Mitchell K et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res. 2011;109:894–906.
54. Chen CW, Okada M, Proto JD et al. Human pericytes for ischemic heart repair. Stem Cells. 2013;31:305–316.
55. Loffredo S, Staiano RI, Granata F, Genovese A, Marone G. Immune cells as a source and target of angiogenic and lymphangiogenic factors. Chem Immunol Allergy. 2014;99:15–36.
56. Leid J, Carrelha J, Boukarabila H, Epelman S, Jacobsen SE, Lavine KJ. Primitive embryonic macrophages are required for coronary development and maturation. Circ Res. 2016;118:1498–1511.
57. Zhang H, Faber JE. De-novo collateral formation following acute myocardial infarction: dependence on CCR2(+) bone marrow cells. J Mol Cell Cardiol. 2015;87:4–16.
58. Chambers SE, O'Neill CL, O'Doherty TM, Medina RJ, Stitt AW. The role of immune-related myeloid cells in angiogenesis. Immunobiology. 2013;218:1370–1375.
59. Riley PR, Smart N. Vascularizing the heart. Cardiovasc Res. 2011;91:260–268.
60. Tian X, Pu WT, Zhou B. Cellular origin and developmental program of coronary angiogenesis. Circ Res. 2015;116:515–530.
61. Tomanek RJ. Formation of the coronary vasculature during development. Angiogenesis. 2005;8:273–284.
62. Hood LC, Rosenquist TH. Coronary artery development in the chick: origin and deployment of smooth muscle cells, and the effects of neural crest ablation. Anat Rec. 1992;234:291–300.
63. Klotz L, Norman S, Vieira JM et al. Cardiac lymphatics are heterogeneous in origin and respond to injury. Nature. 2015;522:62–67.
64. Cai CL, Martin JC, Sun Y et al. A myocardial lineage derives from Tbx18 epicardial cells. Nature. 2008;454:104–108.
65. Dettman RW, Pae S, Morabito C, Bristow J. Inhibition of a4-integrin stimulates epicardial-mesenchymal transformation and alters migration and cell fate of epicardially derived mesenchyme. Dev Biol. 2003;257:315–328.
66. Gittenberger-de Groot AC, Vrancken Peeters MP, Mentink MMT, Gourdie RG, Poelmann RE. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circ Res. 1998;82:1043–1052.
67. Katz TC, Singh MK, Degenhardt K et al. Distinct compartments of the proepicardial organ give rise to coronary vascular endothelial cells. Dev Cell. 2012;22:639–650.
68. Mikawa T. Retroviral targeting of FGF and FGFR in cardiomyocytes and coronary vascular cells during heart development. Ann N Y Acad Sci. 1995;752:506–516.
69. Mikawa T, Gourdie RG. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev Biol. 1996;174:221–232.
70. Volz KS, Jacobs AH, Chen HI et al. Pericytes are progenitors for coronary artery smooth muscle. Elife. 2015;4. e10036.
71. Vrancken Peeters MP, Gittenberger-de Groot AC, Mentink MMT, Poelmann RE. Smooth muscle cells and fibroblasts of the coronary arteries derive from epithelial-mesenchymal transformation of the epicardium. Anat Embryol. 1999;199:367–378.
72. Zhou B, Ma Q, Rajagopal S et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008;454:109–113.
73. Perez-Pomares JM, Macias D, Garcia-Garrido L, Munoz-Chapuli R. Contribution of the primitive epicardium to the subepicardial mesenchyme in hamster and chick embryos. Dev Dyn. 1997;210:96–105.
74. Perez-Pomares JM, Macias D, Garcia-Garrido L, Munoz-Chapuli R. The origin of the subepicardial mesenchyme in the avian embryo: an immunohistochemical and quail-chick chimera study. Dev Biol. 1998;200:57–68.
75. Zhang H, Pu W, Li G et al. Endocardium minimally contributes to coronary endothelium in the embryonic ventricular free walls. Circ Res. 2016;118:1880–1893.
76. Lie-Venema H, Eralp I, Maas S, Gittenberger-de Groot AC, Poelmann RE, DeRuiter MC. Myocardial heterogeneity in permissiveness for epicardium-derived cells and endothelial precursor cells along the developing heart tube at the onset of coronary vascularization. Anat Rec A Discov Mol Cell Evol Biol. 2005;282A:120–129.
77. Poelmann RE, Gittenberger-de Groot AC, Mentink MM, Bokenkamp R, Hogers B. Development of the cardiac coronary vascular endothelium, studied with antiendothelial antibodies, in chicken-quail chimeras. Circ Res. 1993;73:559–568.
78. Mikawa T, Fischman DA. Retroviral analysis of cardiac morphogenesis: discontinuous formation of coronary vessels. Proc Natl Acad Sci USA. 1992;89:9504–9508.
79. Wu B, Zhang Z, Lui W et al. Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. Cell. 2012;151:1083–1096.
80. Misfeldt AM, Boyle SC, Tompkins KL, Bautch VL, Labosky PA, Baldwin HS. Endocardial cells are a distinct endothelial lineage derived from Flk1+ multipotent cardiovascular progenitors. Dev Biol. 2009;333:78–89.
81. Combs MD, Braitsch CM, Lange AW, James JF, Yutzey KE. NFATC1 promotes epicardium-derived cell invasion into myocardium. Development. 2011;138:1747–1757.
82. Duim SN, Kurakula K, Goumans MJ, Kruithof BP. Cardiac endothelial cells express Wilms’ tumor-1: Wt1 expression in the developing, adult and infarcted heart. J Mol Cell Cardiol. 2015;81:127–135.
83. Wagner KD, Wagner N, Bondke A et al. The Wilms’ tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. FASEB J. 2002;16:1117–1119.
84. Christoffels VM, Grieskamp T, Norden J, Mommersteeg MT, Rudat C, Kispert A. Tbx18 and the fate of epicardial progenitors. Nature. 2009;458:E8–E9.
85. Merki E, Zamora M, Raya A et al. Epicardial retinoid X receptor alpha is required for myocardial growth and coronary artery formation. Proc Natl Acad Sci USA. 2005;102:18455–18460.
86. Rudat C, Norden J, Taketo MM, Kispert A. Epicardial function of canonical Wnt-, Hedgehog-, Fgfr1/2-, and Pdgfra-signalling. Cardiovasc Res. 2013;100:411–421.
87. Riley PR. An epicardial floor plan for building and rebuilding the mammalian heart. Curr Top Dev Biol. 2012;100:233–251.
88. Red-Horse K, Ueno H, Weissman IL, Krasnow MA. Coronary arteries form by developmental reprogramming of venous cells. Nature. 2010;464:549–553.
89. Chen HI, Sharma B, Akerberg BN et al. The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis. Development. 2014;141:4500–4512.
90. Puceat M. Embryological origin of the endocardium and derived valve progenitor cells: from developmental biology to stem cell-based valve repair. Biochim Biophys Acta. 1833;917–922:2013.
91. Tian X, Hu T, Zhang H et al. Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res. 2013;23:1075–1090.
92. Smart N, Dube KN, Riley PR. Coronary vessel development and insight towards neovascular therapy. Int J Exp Pathol. 2009;90:262–283.
93. Singh A, Ramesh S, Cibi DM et al. Hippo signaling mediators Yap and Taz Are required in the epicardium for coronary vasculature development. Cell Rep. 2016;15:1384–1393.
94. Tomanek RJ, Sandra A, Zheng W, Brock T, Bjercke RJ, Holifield JS. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis. Circ Res. 2001;88:1135–1141.
95. van Groningen JP, Wenink AC, Testers LH. Myocardial capillaries: increase in number by splitting of existing vessels. Anat Embryol. 1991;184:65–70.
96. Tian X, Hu T, Zhang H et al. Vessel formation. De novo formation of a distinct coronary vascular population in neonatal heart. Science. 2014;345:90–94.
97. Dyer L, Pi X, Patterson C. Connecting the coronaries: how the coronary plexus develops and is functionalized. Dev Biol. 2014;395:111–119.
98. Kattan J, Dettman RW, Bristow J. Formation and remodeling of the coronary vascular bed in the embryonic avian heart. Dev Dyn. 2004;230:34–43.
99. Poelmann RE, Lie-Venema H, Gittenberger-de Groot AC. The role of the epicardium and neural crest as extracardiac contributors to coronary vascular development. Tex Heart Inst J. 2002;29:255–261.
100. Mellgren AM, Smith CL, Olsen GS et al. Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. Circ Res. 2008;103:1393–1401.
101. Smith CL, Baek ST, Sung CY, Tallquist MD. Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling/novelty and significance. Circ Res. 2011;108:e15–e26.
102. Wei K, Diaz-Trelles R, Liu Q et al. Developmental origin of age-related coronary artery disease. Cardiovasc Res. 2015;107:287–294.
103. Liu Q, Zhang H, Tian X et al. Smooth muscle origin of postnatal 2nd CVP is pre-determined in early embryo. Biochem Biophys Res Commun. 2016;471:430–436.
104. Chen TH, Chang TC, Kang JO et al. Epicardial induction of fetal cardiomyocyte proliferation via a retinoic acid-inducible trophic factor. Dev Biol. 2002;250:198–207.
105. Smart N, Bollini S, Dube KN et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474:640–644.
106. Zhou B, Honor LB, He H et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest. 2011;121:1894–1904.
107. Zhou B, Pu WT. Epicardial epithelial to mesenchymal transition in injured heart. J Cell Mol Med. 2011;15:2781–2786.
108. Miquerol L, Thireau J, Bideaux P, Sturny R, Richard S, Kelly RG. Endothelial plasticity drives arterial remodeling within the endocardium after myocardial infarction. Circ Res. 2015;116:1765–1771.
109. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. 2002;298:2188–2190.
110. Lepilina A, Coon AN, Kikuchi K et al. A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. Cell. 2006;127:607–619.
111. Kikuchi K, Gupta V, Wang J et al. tcf21 + epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. Development. 2011;138:2895–2902.
112. Gittenberger-de Groot AC, Winter EM, Poelmann RE. Epicardium-derived cells (EPDCs) in development, cardiac disease and repair of ischemia. J Cell Mol Med. 2010;14:1056–1060.
113. Zhou B, Honor LB, Ma Q et al. Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J Mol Cell Cardiol. 2011;52:43–47.
114. Olivey HE, Svensson EC. Epicardial-myocardial signaling directing coronary vasculogenesis. Circ Res. 2010;106:818–832.
115. Smart N, Riley PR. The epicardium as a candidate for heart regeneration. Future Cardiol. 2012;8:53–69.
116. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–563.
117. Lavine KJ, White AC, Park C et al. Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development. Genes Dev. 2006;20:1651–1666.
118. Tomanek RJ, Ratajska A, Kitten GT, Yue X, Sandra A. Vascular endothelial growth factor expression coincides with coronary vasculogenesis and angiogenesis. Dev Dyn. 1999;215:54–61.
119. Zhang H, Pu W, Tian X et al. Genetic lineage tracing identifies endocardial origin of liver vasculature. Nat Genet. 2016;48:537–543.
120. Zhang Z, Zhou B. Accelerated coronary angiogenesis by vegfr1-knockout endocardial cells. PLoS One. 2013;8:e70570.
121. Tomanek RJ, Zheng W, Peters KG, Lin P, Holifield JS, Suvarna PR. Multiple growth factors regulate coronary embryonic vasculogenesis. Dev Dyn. 2001;221:265–273.
122. Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res. 2010;80:188–194.
123. Yang Z, von Ballmoos MW, Faessler D et al. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. Atherosclerosis. 2010;211:103–109.
124. Takahashi M, Li TS, Suzuki R et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol. 2006;291:H886–H893.
125. Cheng C, Li P, Wang YG, Bi MH, Wu PS. Study on the expression of VEGF and HIF-1alpha in infarct area of rats with AMI. Eur Rev Med Pharmacol Sci. 2016;20:115–119.
126. Ward NL, Van SP, Sturk C, Cruz M, Dumont DJ. Angiopoietin 1 expression levels in the myocardium direct coronary vessel development. Dev Dyn. 2004;229:500–509.
127. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA. 2002;99:8219–8224.
128. Shyu KG, Chang CC, Wang BW, Kuan P, Chang H. Increased expression of angiopoietin-2 and Tie2 receptor in a rat model of myocardial ischaemia/reperfusion. Clin Sci. 2003;105:287–294.
129. Iribarren C, Phelps BH, Darbinian JA et al. Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study. BMC Cardiovasc Disord. 2011;11:31.
130. van Wijk B, Gunst QD, Moorman AF, van den Hoff MJ. Cardiac regeneration from activated epicardium. PLoS One. 2012;7:e44692.
131. House SL, Wang J, Castro AM, Weinheimer C, Kovacs A, Ornitz DM. Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury. Physiol Rep. 2015;3.
132. Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y. Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int J Cardiol. 2010;152:307–313.
133. House SL, Castro AM, Lupu TS et al. Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2016;310:H559–H571.
134. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010;9:4461–4468.
135. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16:1400–1406.
136. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke DP. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002;21:1743–1753.
137. Craig EA, Parker P, Austin AF, Barnett JV, Camenisch TD. Involvement of the MEKK1 signaling pathway in the regulation of epicardial cell behavior by hyaluronan. Cell Signal. 2010;22:968–976.
138. Olivey HE, Mundell NA, Austin AF, Barnett JV. Transforming growth factor-beta stimulates epithelial-mesenchymal transformation in the proepicardium. Dev Dyn. 2006;235:50–59.
139. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184–195.
140. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 2011;50:522–533.
141. Bax NA, Bleyl SB, Gallini R et al. Cardiac malformations in Pdgfralpha mutant embryos are associated with increased expression of WT1 and Nkx2.5 in the second heart field. Dev Dyn. 2010;239:2307–2317.
142. Lu J, Landerholm TE, Wei JS et al. Coronary smooth muscle differentiation from proepicardial cells requires rhoA-mediated actin reorganization and p160 rho-kinase activity. Dev Biol. 2001;240:404–418.
143. Zymek P, Bujak M, Chatila K et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol. 2006;48:2315–2323.
144. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126:3597–3605.
145. Ueda K, Takano H, Niitsuma Y et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest. 2010;120:2016–2029.
146. Westenbrink BD, Ruifrok WP, Voors AA et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res. 2010;87:30–39.
147. Xu W, Guo Z, Mi L, Wang G. Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion. Biomarkers. 2013;18:343–348.
148. Yuksel IO, Cagirci G, Koklu E et al. Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion. Neth Heart J. 2016;24:609–616.
149. Sainson RC, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 2008;11:41–51.
150. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011;12:551–564.
151. del Monte G, Casanova JC, Guadix JA et al. Differential Notch signaling in the epicardium is required for cardiac inflow development and coronary vessel morphogenesis. Circ Res. 2011;108:824–836.
152. Raya A, Koth CM, Buscher D et al. Activation of Notch signaling pathway precedes heart regeneration in zebrafish. Proc Natl Acad Sci USA. 2003;100(Suppl 1):11889–11895.
153. Croquelois A, Domenighetti AA, Nemir M et al. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. J Exp Med. 2008;205:3173–3185.
154. Russell JL, Goetsch SC, Gaiano NR, Hill JA, Olson EN, Schneider JW. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. Circ Res. 2011;108:51–59.
155. Awada HK, Johnson NR, Wang Y. Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction. J Control Release. 2015;207:7–17.
156. Zheng W, Weiss RM, Wang X et al. DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am J Physiol Heart Circ Physiol. 2004;286:H1994–H2000.
157. Ballantyne MD, McDonald RA, Baker AH. lncRNA/MicroRNA interactions in the vasculature. Clin Pharmacol Ther. 2016;99:494–501.
158. Fang YC, Yeh CH. Role of microRNAs in vascular remodeling. Curr Mol Med. 2015;15:684–696.
159. Leung A, Stapleton K, Natarajan R. Functional long non-coding RNAs in vascular smooth muscle cells. Curr Top Microbiol Immunol. 2016;394:127–141.
160. Song X, Shan D, Chen J, Jing Q. miRNAs and lncRNAs in vascular injury and remodeling. Sci China Life Sci. 2014;57:826–835.
161. Uchida S, Dimmeler S. Long noncoding RNAs in cardiovascular diseases. Circ Res. 2015;116:737–750.
162. Chistiakov DA, Orekhov AN, Bobryshev YV. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. J Mol Cell Cardiol. 2016;97:47–55.
163. Smart N, Risebro CA, Melville AAD et al. Thymosin b4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445:177–182.
164. Smart N, Bollini S, Dube KN et al. Myocardial regeneration: expanding the repertoire of thymosin beta4 in the ischemic heart. Ann N Y Acad Sci. 2012;1269:92–101.
165. Smart N, Risebro CA, Clark JE et al. Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart. Ann N Y Acad Sci. 2010;1194:97–104.
166. Bollini S, Vieira JM, Howard S et al. Re-activated adult epicardial progenitor cells are a heterogeneous population molecularly distinct from their embryonic counterparts. Stem Cells Dev. 2014;23:1719–1730.
167. Moretti A, Caron L, Nakano A et al. Multipotent embryonic isl1 + progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell. 2006;127:1151–1165.
168. Urayama K, Guilini C, Turkeri G et al. Prokineticin receptor-1 induces neovascularization and epicardial-derived progenitor cell differentiation. Arterioscler Thromb Vasc Biol. 2008;28:841–849.
169. Boulberdaa M, Urayama K, Nebigil CG. Prokineticin receptor-1 (PKR1) signaling in cardiovascular and kidney functions. Cardiovasc Res. 2011;92:191–198.
170. Lui KO, Zangi L, Silva EA et al. Driving vascular endothelial cell fate of human multipotent Isl1(+) heart progenitors with VEGF modified mRNA. Cell Res. 2013;23:1172–1186.
171. Zangi L, Lui KO, von Gise A et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31:898–907.
172. Xiang FL, Liu Y, Lu X, Jones DL, Feng Q. Cardiac-specific overexpression of human stem cell factor promotes epicardial activation and arteriogenesis after myocardial infarction. Circ Heart Fail. 2014;7:831–842.
173. Limana F, Bertolami C, Mangoni A et al. Myocardial infarction induces embryonic reprogramming of epicardial c-kit(+) cells: role of the pericardial fluid. J Mol Cell Cardiol. 2010;48:609–618.
174. Limana F, Zacheo A, Mocini D et al. Identification of myocardial and vascular precursor cells in human and mouse epicardium. Circ Res. 2007;101:1255–1265.